Ozanimod Approved for Relapsing Forms of Multiple Sclerosis

Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues.

Source link

Related posts

Histopathology of diffusion imaging abnormalities in cerebral amyloid angiopathy


Hemodynamic assessments of venous pulsatile tinnitus using 4D-flow MRI


Pearls & Oy-sters: Hydroxychloroquine-induced toxic myopathy mimics Pompe disease: Critical role of genetic test


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy